BioSpace News Archive

Second-Quarter 2019 Net Sales of $320.6 Million Increased 6 Percent; Second-Quarter 2019 GAAP Net Loss of $5.1 Million; Adjusted EBITDA of $124.1 Million

The global hepatitis C drugs market size is poised to decline by USD billion during 2019-2023, according to a new report by Technavio, decelerating at a CAGR of close to% over the forecast period.

Company Names Jessica Holmes VP of Health Policy & Reimbursement, Brian Regan VP of Strategy & Professional Relations, and Jim Sluck VP of Dry Eye Marketing

Rimegepant is the only oral CGRP receptor antagonist currently in development for both the acute and preventive treatment of migraine

Nasdaq has granted the Company’s request for continued listing of the Company’s stock on the Nasdaq Stock Market.

The Co-operators and BDC Capital co-lead investment that will expand AI-driven infectious disease global early warning system

The global seborrheic keratosis treatment market size is poised to reach USD 634 million by 2023, according to a new report by Technavio, progressing at a CAGR of 6% during the forecast period.

Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Cambrex Corporation breached their fiduciary duties in connection with the proposed sale of the Company to private equity firm Permira.

Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today that it will report its financial results for the second quarter ended June 30th, 2019

Friedberg will lead the company’s performance measurement and improvement efforts